Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 489,633 shares, a growth of 77.6% from the April 15th total of 275,689 shares. Based on an average daily trading volume, of 681,214 shares, the days-to-cover ratio is presently 0.7 days. Currently, 8.6% of the company’s shares are short sold.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds have recently modified their holdings of the stock. SummitTX Capital L.P. raised its holdings in shares of Aligos Therapeutics by 6.7% during the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after buying an additional 9,375 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Aligos Therapeutics by 17.6% during the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after buying an additional 15,006 shares during the period. Rockefeller Capital Management L.P. raised its holdings in shares of Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares during the period. XTX Topco Ltd purchased a new stake in shares of Aligos Therapeutics during the 4th quarter valued at about $215,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Aligos Therapeutics during the 4th quarter valued at about $664,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Aligos Therapeutics Price Performance

Aligos Therapeutics stock opened at $5.71 on Monday. The stock’s 50-day moving average is $7.02 and its 200-day moving average is $8.01. The company has a market cap of $35.34 million, a price-to-earnings ratio of -0.66 and a beta of 2.28. Aligos Therapeutics has a 12 month low of $5.12 and a 12 month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, beating the consensus estimate of ($2.29) by $0.08. The business had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. Research analysts anticipate that Aligos Therapeutics will post -7.54 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ALGS shares. Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. Westpark Capital started coverage on Aligos Therapeutics in a research report on Thursday, March 26th. They set a “buy” rating and a $48.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Finally, Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.